Last reviewed · How we verify
NCT04645589
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
trial testing Myfortic in Lupus Nephritis in 72 participants. Completed in 13 June 2025.
13 June 2025
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 16 March 2021 |
| Primary completion | 13 June 2025 |
| Estimated completion | 13 June 2025 |
| Sites | 6 locations across Taiwan |
Drugs / interventions tested
- Myfortic — full drug profile →
Conditions studied
- Lupus Nephritis — all drugs for Lupus Nephritis →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 20 to 75, any sex, with Lupus Nephritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, prospective, single-arm, observational study in patients with Lupus nephritis (LN) who newly (i.e.,for the first time) received treatment of Enteric-coated Mycophenolate Sodium (EC-MPS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04645589
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Myfortic
Trials testing the same drug.
- NCT02130817 — Belatacept in Kidney Transplantation of Moderately Sensitized Patients · Phase 4 · withdrawn
Other recruiting trials for Lupus Nephritis
Currently open trials in the same condition.
- NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
- NCT07109986 — UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis · Phase 1 · recruiting
- NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
- NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
- NCT06711887 — Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants · Phase 3 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04645589 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04645589.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing